The Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why

Simply Wall St.06-11

Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642473871?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-11 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642473871","market":"us","top_or_hot":-1,"title":"The Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why","media":"Simply Wall St.","content":"<div>\n<p>Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bull Case For Immunocore Holdings (IMCR) Could Change Following New Brenetafusp Melanoma Data - Learn Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-11 01:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll","article_id":"2642473871","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/the-bull-case-for-immunocore-holdings-imcr-could-change-foll","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642473871","pubTimestamp":1781112014,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that informed selection of a 160 mcg dose for its ongoing Phase 3 PRISM-MEL-301 trial.\nThe results presented at ASCO 2026 also suggested potential benefit in patients with primary PD-1 resistance and hinted at further upside from combinations, including with IL7, which could broaden the future role...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","IMCR":"Immunocore Holdings plc","AGIX":"通用人工智能 ETF-AGIX","BK4587":"ChatGPT概念","BK4543":"AI","BK4139":"生物科技","AI":"C3.ai, Inc.","BK4551":"寇图资本持仓","BK4505":"高瓴资本持仓","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4023":"应用软件","BK4528":"SaaS概念","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"根据新的Brenetafusp黑色素瘤数据，Immunocore Holdings(IMCR)的牛市可能会发生变化-了解原因","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1.5,"ARTY":0.73,"AIPO":0.84,"CHAT":0.73,"AGIX":0.73,"AI":0.73,"AIYY":0.6},"content_text":"Immunocore Holdings recently reported updated Phase 1/2 data for its ImmTAC molecule brenetafusp in heavily pretreated advanced melanoma, showing encouraging survival and disease control outcomes that informed selection of a 160 mcg dose for its ongoing Phase 3 PRISM-MEL-301 trial. The results presented at ASCO 2026 also suggested potential benefit in patients with primary PD-1 resistance and hinted at further upside from combinations, including with IL7, which could broaden the future role of ImmTAC therapies across difficult-to-treat tumors. Next, we’ll examine how these brenetafusp data in PD-1–resistant melanoma could reshape Immunocore’s investment narrative and pipeline expectations. Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementImmunocore Holdings Investment Narrative RecapTo own Immunocore, you need to believe its ImmTAC platform can turn KIMMTRAK’s uveal melanoma foothold into a broader oncology franchise, with brenetafusp in first line advanced melanoma a key test. The updated Phase 1/2 data strengthen the rationale for the Phase 3 PRISM-MEL trial and slightly improve visibility on that near term catalyst, but they do not remove the central risk that pivotal outcomes, timelines and eventual uptake may fall short of expectations. Among recent announcements, the appointment of Anne Achola Sefu to the board matters most here, as fresh board oversight comes just as Immunocore leans further into late stage investment around brenetafusp and other ImmTAC assets. That added governance experience may influence how the company balances growing R&D spend, dependence on KIMMTRAK and decisions around future combinations or indications that could follow from the PRISM-MEL program. Yet behind the encouraging melanoma data, investors should still be aware that prolonged R&D spending and any setback in PRISM-MEL could... Read the full narrative on Immunocore Holdings (it's free!)Immunocore Holdings' narrative projects $551.3 million revenue and $88.5 million earnings by 2028.Uncover how Immunocore Holdings' forecasts yield a $66.57 fair value, a 133% upside to its current price.Exploring Other PerspectivesIMCR 1-Year Stock Price Chart Some analysts were already far more optimistic, assuming around US$655 million of revenue and positive earnings by 2028, so this new melanoma data could either reinforce or challenge that view.Explore 3 other fair value estimates on Immunocore Holdings - why the stock might be worth just $63.49!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Immunocore Holdings research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Immunocore Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunocore Holdings' overall financial health at a glance.Ready For A Different Approach?Our top stock finds are flying under the radar-for now. Get in early:The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.Outshine the giants: these 14 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642473871","isCrawlerRequest":true}